FIELD: biotechnology.
SUBSTANCE: population of Tr1-cells directed against an antigen associated with disseminated sclerosis and having quiescent phenotype CD4+CD25-FoxP3- is isolated. The resulting population of Tr1-cells in combination with one or more pharmaceutically acceptable carriers, or in combination with one or more pharmaceutical agents used for treating disseminated sclerosis, selected from the group comprising interferon-beta, glatimer acetate, mitoxantrone, cyclophosphamide, methotrexate, asitropine, or natalizumab is used in pharmaceutical compositions for treating disseminated sclerosis.
EFFECT: invention enables to obtain an effective remedy for treating disseminated sclerosis.
11 cl, 2 dwg
